GIP/GLP-1 & amylin agonists × body weight & composition

SynthesisEndocrinology, diabetes & metabolism2025

Tirzepatide Versus Semaglutide on Weight Loss in Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis of Direct Comparative Studies.

Jimmy Wen et al.PubMed ↗Full text ↗Publisher ↗

  • Tirzepatidelooks good hereLower weight loss.Randomised, large.

What the trial testedrandomised · 28,827 people · 2025

Randomised vs semaglutide

Lowered weight loss

−4.84kg−6.21 to −3.47

tirzepatide vs semaglutide

As reported

difference −4.84 kg, 95% CI −6.21 to −3.47

Who was studied, and how

28,827people with type 2 diabetes, in this paper

The trial randomly assignedassigned by chance

tirzepatide
semaglutide

Lowered weight loss−4.84

randomised

the abstract, start to end

these findings with a mean difference of -4.84 kg (95% CI: -6.21 to -3.47),

← favours treatmentfavours comparator →
could be chance
Weight losstirzepatide vs semaglutide
−4.84−6.21 to −3.47
GIP/GLP-1 & amylin agonistsBody weight & composition
1 / 4

9 papers cite it

2025
2026
this papercites it
Full record →Abstract, authors, funding and every citing paper · PMID 40184508